Publications by authors named "J-B Prevost"
Article Synopsis
- - The study analyzes plasma samples from 318 COVID-19 patients to understand how RNAemia, delayed antibody responses, and inflammation affect patient outcomes, revealing four distinct patient clusters based on severity and survival probability.
- - Critically ill patients were categorized into good prognosis and high-fatality clusters, while non-critical survivors were divided into high and low early antibody responders, each showing different patterns in antibody development and inflammation.
- - The findings indicate that high-fatality patients have specific genomic signatures linked to severe COVID-19, and both critical and non-critical patients with delayed antibody responses exhibit persistent interferon (IFN) activity, suggesting that high IFN levels might hinder the body's ability to build effective immunity.
Objectives: Whole-body magnetic resonance imaging (WB-MRI) has been demonstrated to be efficient and cost-effective for cancer staging. The study aim was to develop a machine learning (ML) algorithm to improve radiologists' sensitivity and specificity for metastasis detection and reduce reading times.
Materials And Methods: A retrospective analysis of 438 prospectively collected WB-MRI scans from multicenter Streamline studies (February 2013-September 2016) was undertaken.
The HIV-1 envelope glycoprotein (Env) (gp120-gp41) is the target for neutralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC). HIV-1 Env is flexible, sampling different conformational states. Before engaging CD4, Env adopts a closed conformation (State 1) that is largely antibody resistant.
View Article and Find Full Text PDFThe anti-tumour and anti-metastatic properties of heparins have not been tested in patients with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin impacts the survival of patients with resected non-small cell lung cancer (NSCLC) was investigated.Patients with completely resected stage I, II or IIIA NSCLC were randomly allocated to receive subcutaneous tinzaparin 100 IU·kg once a day for 12 weeks or no treatment in addition to standard of care.
View Article and Find Full Text PDF